|Bid||0.00 x 45100|
|Ask||0.00 x 41800|
|Day's Range||19.98 - 20.00|
|52 Week Range||3.15 - 20.45|
|Beta (5Y Monthly)||2.48|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]
A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of investigational therapies that would grow those markets is exciting investors.
Principia Biopharma stock has rocketed 32% this week amid enthusiasm for its technology, BTK inhibition — highlighted by notable moves from pharmaceutical giants Merck and Sanofi.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
A string of multibillion-dollar pharmaceutical deals announced over the last week call attention to a record-setting year in which drugmakers and biotechs have spent $342 billion snapping up smaller companies to bolster their pipelines.
Dow book a triple-digit loss Monday, and all three major U.S. stock indexes end lower, as investors wait on global central bank policy updates this week and a key tariff deadline on Sunday.
ArQule stock rocketed more than 100% on Monday after Dow Jones stock Merck pledged to buy it for $2.7 billion. The biotech company is working on precision medicine in cancer treatment.
U.S. stocks pulled back on Monday from near-record levels, as Apple and healthcare shares fell and investors braced for a busy week of political and economic news, including a potential turning point in the U.S.-China trade dispute. Investor hopes of at least an initial U.S.-China agreement have helped push major stock indexes to record highs, with the benchmark S&P 500 hovering about 0.5% below its all-time high. "The market is ... in a little bit of a wait-and-see mode," said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.
"There is optimism about the potential of a roll back or some positive news on trade that is keeping stocks where they are," said Randy Frederick, vice president of trading and derivatives for Charles Schwab in Austin, Texas. The S&P 500 came within striking distance of a record high hit two weeks ago.
Continuing with last's week trend of consolidation in the industry, two major players Merck (NYSE: MRK) and Sanofi (NYSE: SNY), made acquisitions to bolster their pipeline and augment future growth. One was telegraphed by the price action at the end of last week and the other was kept under wraps. The price action last week in Arqule Inc (NASDAQ: ARQL) gave no indication that the company was going to be taken out for $20/share as it posted a modest 9-cent gain for the week.
Benzinga Pro's Stocks To Watch For Monday Merck (MRK) - Reported it will purchase ArQule (ARQL) in a deal valued at $2.7 billion. The purchase price for ArQule was $20/share in cash. ArQule shares were ...
Merck entered into a $2.7 billion deal Monday to buy ArQule Inc., a Massachusetts-based biopharmaceutical company developing targeted therapies for cancer and rare diseases. Under the terms of the cash deal, which still requires regulatory and shareholder approval, Merck (NYSE: MRK) will pay $20 per share to ArQule (NASDAQ: ARQL) stockholders. The offer is more than a 100% premium over the $9.66 share price ArQule closed at on Friday.
"There is optimism about the potential of a roll back or some positive news on trade that is keeping stocks where they are," said Randy Frederick, vice president of trading and derivatives for Charles Schwab in Austin, Texas. The latest data from China showed exports in November shrank for the fourth consecutive month, underscoring persistent pressures on manufacturers from trade tensions.
The S&P 500 and Nasdaq indexes edged higher on Monday, with investors keeping a close watch on headlines around U.S.-China trade as planned tariffs on Chinese imports kick in on Dec. 15. Beijing and Washington are negotiating a first phase trade deal aimed at de-escalating tariff disputes but they continue to wrangle over key details.
Drug giant Merck & Co. announced Monday that it will spend billions to buy a local biotech company that has struggled to bring a cancer drug to market.